Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic Vγ9Vδ2 T cell therapy
- Development stage
- Phase 2
- Lead developer
- Fuda Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an allogeneic cell therapy consisting of Vγ9Vδ2 T cells expanded from healthy donor peripheral blood mononuclear cells (PBMCs). Developed by Fuda Cancer Hospital in Guangzhou, it is designed to treat liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The therapy utilizes the innate-like properties of γδ T cells, which recognize and kill tumor cells in an HLA-independent manner. It has been studied as a standalone treatment and in combination with local ablation techniques like cryosurgery or irreversible electroporation (IRE) to enhance clinical outcomes in late-stage patients.
- Other names
- γδ T cell immunotherapyallogeneic γδ T cellsVγ9Vδ2 T cells
02
Targets
NKG2D (Natural killer group 2 member D receptor)BTN3A1 (Butyrophilin subfamily 3 member A1)BTN2A1 (Butyrophilin subfamily 2 member A1)
Beyond the preview
Go deeper on allogeneic Vγ9Vδ2 T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic Vγ9Vδ2 T cell therapy.